---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027835"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-08-14T12:30:19+00:00"
generated_at: "2026-08-14T12:35:25.762694+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moleculin Q2 2026: MIRACLE CR rates 3x control, cash runway into Q1 2027

## Summary
- MIRACLE interim data: CR 43% (190 mg/m²) and 36% (230 mg/m²) vs 12% control; CRc 50% and 57% vs 29%.
- Enrollment >80% of 90 patients; data readout Dec 2026-Feb 2027; Part B start 1H 2027.
- Cash $7.3M at June 30 plus $9.3M raised post-quarter; runway into Q1 2027.
- R&D expenses $5.5M in Q2 2026 vs $3.6M YoY; G&A flat at $2.1M.
- No cardiotoxicity observed; ASCO data support cardiac safety profile.

## SEC filing metadata
- accession: 0001437749-26-027835
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-08-14T12:30:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/0001437749-26-027835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/mbrx20260811_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027835
- JSON: https://secwatch.observer/filing/0001437749-26-027835.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.